There is an error in the financial disclosure of “Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions” by Deroose et al. (J Nucl Med. 2016;57:1949–1956). The correct disclosure is as follows: “Dr. Deroose is a consultant/advisor for Sirtex and Ipsen, is a meeting participant/lecturer for Bayer, and is involved in a scientific study/trial for Advanced Accelerator Applications (AAA). AAA (68Ga-DOTATATE, 177Lu-DOTATATE, 18F-DOPA, and 18F-FDG), Sirtex (selective internal radiotherapy spheres), and Ipsen (lanreotide and radiolabeled SSTR antagonists) produce diagnostic and therapeutic agents described in this article.” The authors regret the error.
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
